HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $13.72, but opened at $14.36. HUTCHMED shares last traded at $14.60, with a volume of 11,033 shares.
Analyst Upgrades and Downgrades
Separately, StockNews.com lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a research note on Monday, November 18th.
View Our Latest Stock Report on HCM
HUTCHMED Price Performance
The business's 50 day simple moving average is $14.22 and its 200-day simple moving average is $16.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.
Institutional Investors Weigh In On HUTCHMED
Institutional investors have recently modified their holdings of the stock. Blue Trust Inc. lifted its stake in shares of HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock valued at $69,000 after purchasing an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock valued at $117,000 after purchasing an additional 2,321 shares during the last quarter. M&G PLC lifted its stake in shares of HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company's stock valued at $5,345,000 after purchasing an additional 132,333 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of HUTCHMED in the 3rd quarter valued at $328,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of HUTCHMED by 99.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company's stock valued at $952,000 after purchasing an additional 24,245 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Recommended Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
